- Home
- Browse
- DOT - Federal Transit Administration
- FTA-2026-012-TPM-ICAM
FY 2026 Notice of Funding Opportunity: Innovative Coordinated Access and Mobility Pilot Program
- Deadline
- 2026-09-09
- 6 days left
- Award ceiling
- —
- Awards
- 20
- Posted
- 2026-07-09
Summary
The Federal Transit Administration (FTA) announces the opportunity to apply for $11,959,671 million in Fiscal Year (FY) 2024, 2025, and 2026 competitive grant funding to support transit services for the FY 2026 Innovative Coordinated Access and Mobility (ICAM) pilot program. […]
The rest of this announcement — free with an account
- →The full announcement text, not the first two sentences
- →The scoring framework for this mechanism — we have not extracted per-criterion detail for this specific announcement
- →Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- →What similar funded projects received, from 219,000 past awards
No card required. Browsing and your first match are free.
More from DOT - Federal Transit Administration
See all →Fiscal Year 2026 Competitive Funding Opportunity: Low or No Emission Program
The Federal Transit Administration (FTA) announces the availability of approximately $589 million in competitive grants under the Low or No Emission Grant Program (Low-No Program) for the purchase or lease of low-emission and zero-emission transit buses, including acquisition, construction, and leasing of required supporting facilities.
Fiscal Year 2026 Competitive Funding Opportunity: Buses and Bus Facilities Program
The Federal Transit Administration (FTA) announces the availability of approximately $21 million in competitive grants under the Buses and Bus Facilities Program to assist in the financing of buses and bus facilities capital projects, including replacing, rehabilitating, purchasing or leasing buses or related equipment, and…
Also in infrastructure
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileOfficial announcement: https://www.grants.gov/search-results-detail/363122Source: grants_gov. Always confirm dates with the funder.